SRS was tolerated in patients with melanoma brain metastases treated with either anti-PD-1 or anti-CTLA-4 ICB therapy13–15, with greater reductions in lesion volume for patients treated with ICB therapy and SRS. This evidence concerns the gene CTLA4 and melanoma.